In advanced-stage ERBB2-positive breast cancer patients, several vaccines targeting ERBB2 have shown promise [56,57], although early attempts targeting this protein resulted in only “short-lived peptide-specific immunity” [58,59,60]. Here, ERBB2 is linked to breast carcinoma.